Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-19 · accession 0001788542-23-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-21 | 2023-07-19 | TARS | Mottiwala Aziz | Chief Commercial Off | S - Sale | $20.05 | -2,400 | 45.8K | -5% | -$48.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-19 | S | D | 2,400 | $20.05 | 45,806 | D | — | — | (F2) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) Includes 120 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023. |